Company intelligence / Profile preview

Cangene Corporation

Winnipeg, Manitoba, Canadainvestors.emergentbiosolutions.com ↗

Ownership: Private
Employees: ~75
Development stage: Commercial

Overview

Cangene had several approved commercial products including WinRho, HepaGam B, VARIZIG, and episil, as well as three products in the U.S. Strategic National Stockpile: Heptavalent botulism antitoxin, Vaccinia immune globulin, and Anthrax immune globulin[1][6]

Therapeutic areas: Infectious Diseases
Modalities: Hyperimmunesplasma-derived productsrecombinant biopharmaceuticals
Industry: Biotech

Drug pipeline

5 assets

TST10088

Unknown

4 more assets in the full pipeline.

Request access →

Partnerships

Supply agreement with Spectrum Pharmaceuticals for Fusilev product (May 2008 to May 2013)[1]

Beyond the preview

Go deeper on Cangene Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cangene Corporation.

Explore the full profile